small-molecule new chemical entities (NCEs) were introduced of which ∼34% were either a natural product or a close analogue. While this metric reflects the impact natural products have played in delivering new chemical starting points (leads) for the pharmaceutical industry, it does not capture the decline this approach has suffered over the last 20 years as the high-throughput screening (HTS) of pure compound libraries has become more popular. An impediment to natural product drug discovery in the HTS paradigm is the lack of a clear strategy that enables front-loading of an extract or fraction's chemical constituents so that they are compliant with lead-and drug-like chemical space. To address this imbalance, an approach based on lipophilicity, as measured by clog P has been developed that, together with advances being made in isolation and structural elucidation, can afford natural product leads in timelines compatible with pure compound screening.
Introduction. -Small-molecule drug discovery has changed significantly over the past two decades.
The previous paradigm in which tens-to-hundreds of compounds were tested in animal models was replaced in the early 1990s by the high-throughput screening (HTS) of megalibraries against modified cell lines or isolated biomolecular targets produced by recombinant proteins [1] . These early libraries were typically comprised of molecules that could be produced in a highly efficient manner using combinatorial chemistry techniques [1] .
However, the early period of the HTS era was not without controversy [2] . The vast numbers of compounds that could be efficiently screened was seductive and resulted in unrealistic expectations being placed on combinatorial chemistry and HTS to reverse the lack of new chemical entities (NCEs) emerging from company pipelines. When this did not eventuate, the focus rightly shifted towards increasing the quality of both the libraries, assays and supporting infrastructure [2] . For libraries in particular, this readjustment was driven, in part, by a better understanding of the types of molecules that should be screened and the end point that resulted in a drug [3] .
A turning point for the pharmaceutical industry occurred in 1997 when Lipinski and co-workers reported that the combinatorial chemistry libraries then being screened were simply not comprised of 'drug-like' molecules [4] . They identified four simple physicochemical properties common to the 90 th percentile of more than 2000 drugs and candidate drugs achieving phase II clinical status and, from this, formulated the 'Rule of 5' (Ro5), so-called because the maximum value for each parameter is a multiple of five: molecular weight (MW) < 500; H-bond donors (HBD) < 5; H-bond acceptors (HBA) < 10 and; the calculated log P (clog P) < 5. In essence, the Ro5 is a set of guidelines that identifies key properties for orally administered drugs while, at the same time, highlighting potential bioavailability issues if two or more violations occur [4] .
While the Ro5 recognizes the end point of a drug discovery program, it is the identification of lead compounds, the chemical starting points for further development, that is considered to be critically important [5] . Much emphasis is now placed on addressing physicochemical properties early in contemporary drug discovery [5] and, as a result, many companies routinely screen libraries comprised of molecules with profiles below those dictated by the Ro5. The HTS of 'lead-like ' [6] or 'reduced complexity' [7] sets facilitates downstream chemical optimization which typically adds mass and lipophilicity en route to the final product [5] .
Sometime later, Leeson and Davis proposed that properties remaining consistent over time were actually the most important to be considered [3a] . Their analysis of 864 drug approvals prior to 1983 compared with 329 between 1983-2002 revealed that drug lipophilicity, as estimated by clog P, changed less than other physicochemical properties and concluded log P was the most important parameter. This was not completely unexpected as the role of log P in influencing drug potency, pharmacokinetics and toxicity had already been established [8] .
Despite the fact natural products have remained a fruitful source of lead molecules for the pharmaceutical industry, their popularity has waned considerably over the past 20 years [9] . One of the reasons often cited for disbanding natural products drug discovery has been that the time and resources required to identify leads, generally via iterative bioassay-guided fractionation following screening of extract or prefractionated libraries, is not competitive with the screening of pure compound libraries [10] . However, unlike the pharmaceutical industry that embraced sweeping reforms and is now reaping the benefits [1] [11], the natural product community has seemingly not learned, or applied, these invaluable lessons to its own work streams.
By way of example, classical bioassay-guided fractionation, a mainstay of natural product drug discovery, has only been able to undertake physicochemical profiling after compounds have been isolated and structures elucidated. Until now, there has been no strategy that aligns (i.e. front loads) a natural product screening set with lead-and drug-like properties to assist the downstream triage of biological and chemical data to expedite isolation of actives in timelines approaching that of pure compound libraries. Clearly, an approach based on log P, for example, would advance natural product drug discovery within the HTS paradigm as the molecules would automatically comply with the most important of the physicochemical properties and therefore have a higher probability of progressing from hits to leads, even though their structures may not be known at the time of screening. Fortunately for natural product drug discovery log P lends itself to a chromatographic-based protocol that facilitates construction of a screening library which addresses the lead-and drug-likenesses of its constituents early in the work stream. Herein, we provide details pertaining to the development and implementation of a log P filter for natural product screening extract libraries. Like others [12] [13] , we observed a relationship between the retention of small organic molecules in immobilized octadecanyl chains and log P. Thus, most compounds eluting up to 25 minutes on the HPLC system generally had log P ≤ 5 while those eluting after 25 minutes tended to be higher (Fig. 1a,   Fig 2a) . A similar trend was observed for both the calculated parameters, clog P and clog D 7.4 ( Fig. 1b-c, Fig. 2b-c) allowing the predicted values to be used with a high degree of confidence where empirical data was not available. Interestingly, the plot of experimental data, i.e. log P, was tighter compared with both the calculated sets using a number of different algorithms and may indicate that the training sets in many commercial packages do not yet contain sufficient scaffolds/combinations of functional groups found in natural products.
Results and
Comparison of SPE Sorbents Using Crude Extracts. Having established the desirable upper limit of log P on our HPLC system, we next investigated the ability of various SPE sorbents to retain highly lipophilic constituents in crude extract and, importantly, elute components with log P ≤ 5. Thus, 60 mg equivalents (mge), i.e. the extract derived from 60 mg of either a plant or marine invertebrate, in 500 µl of eluting solvent was loaded onto various SPE sorbents and washed with a further 800 µl of the same solvent. Four different types of sorbent matrices were tested: C 18 -bonded silica, polystyrene, crosslinked poly(styrene-divinylbenzene) and cross-linked poly(N-vinylpyrrolidone-divinylbenzene). Sixteen plant and marine invertebrates were selected from the Griffith University Nature Bank collection for the initial studies ( Table 2 ). The eluent from the load and wash cycles (∼ 4-5 bed volumes depending on sorbent) was collected and analyzed for retention of lipophilic components using a dual diode array detector and evaporative light scattering detector system ( Table 3 ).
The study of eluting solvents was limited to methanol:water (MeOH:H 2 O) mixtures; acetonitrile was not considered for cost and environmental considerations. The N-vinylpyrrolidone-divinylbenzene (NVP-DVB) copolymer was the most effective sorbent for all eluting conditions and especially superior when trifluoroacetic acid (TFA/H + ) was added to the eluent. We have observed that highly lipophilic/nuisance compounds like fatty acids, polyphenolics and sulfated steroids can be major constituents of crude extracts derived from plant and marine invertebrates. These molecules are maintained in the neutral form in the presence of acid which facilitates retention [14] .
It was interesting to note that the two styrene-based sorbents did not retain as much of the unwanted lipophilic molecules as the NVP-DVB copolymer. This observation would suggest that screening sets derived from a similar polystyrene sorbent to that used here (i.e., Diaion HP-20SS) [15] , may contain molecules that are not drug-like and typically manifest themselves as frequent hitters in biological assays. However, this is still preferred to screening crude extracts, particularly those derived from hexanes, which we and others [16] have found typically contain fatty acids and other lipophilic material. Refining the Eluting Solvent for the NVP-DVB copolymer. Given the NVP-DVB sorbent retained highly lipophilic components from crude extracts more strongly than other matrices, we next set out to refine the eluting conditions. Eleven reference compounds were selected from the pure natural product and drug sets spanning a clog P range between -7.60 to 7.45, and to this was added two more natural products, eupomatenoid 3, and eupomatenoid 5, with log P ∼5. ( Table 1 ). The molecules in this subset were used as both mixtures of pure compounds and as internal standards in crude extracts to strike an acceptable balance between recovery and selectivity of compounds with desired log P profiles.
When employed as a mixture of pure compounds, a good recovery of components with log P < 4 was possible when 70:30 MeOH:H 2 O/H + (10 bed volumes) was used as the first solvent, and 90:10
MeOH:H 2 O/H + (10 bed volumes) as the second. Good to excellent recoveries were typically obtained for constituents in which the calculated and experimental log P < 5 as shown in Fig. 3 . Components in which the calculated and experimental log P > 5, e.g. rapamycin (clog P = 7.45), were retained using this combination of sorbent and solvent (Fig. 3) .
Fig. 3. Elution profile of natural product drugs: vancomycin (A); brucine (B); metaprolol (C); reserpine (D); mycophenolic acid (E); taxol (F); capsaicin (G); and rapamycin (H). The red spectrum corresponds to a UV trace at 248 nm; black at 274 nm. The peak at 15 minutes is due to decomposition of vancomycin following drying at reduced pressure.
Eluting conditions for crude extracts were next carried out using the above results from pure compounds as a guide. In the first set of experiments, 60 mge of two crude extracts known to contain high amounts of lipophilic material ( The preliminary experiments augured well for scale up from 60 mge of extract to 300 mge extract.
Thus, an additional six samples (Table 2 ) were added to the set and all 23 biota extracted using the procedures described in the Experimental Part (vide infra) and loaded onto SPE cartridges packed with 300, 400 and 600 mg of the NVP-DVB copolymer. We found that 4.5 ml of the load solvent (70:30
MeOH:H 2 O/H + ) was necessary to solubilize the crude extracts. An additional 8 ml of load solvent (i.e.
12.5 ml total, ∼10 bed volumes) was used to afford the first lead-like enhanced (LLE) extract. The second LLE extract was obtained using 90:10 MeOH:H 2 O/H + (12.5 ml). Under these conditions, 400 mg of sorbent proved sufficiently effective at retaining later eluting material and avoiding breakthrough.
The sorbent and dual solvent system was next analyzed using the six extracts spiked with brucine, theophylline and clotrimazole. Each reference compound was recovered in the same quantity when combined with an extract as in pure form. This result prompted a further set of experiments in which crude extracts were spiked with different reference compounds that did not co-elute with innate constituents. In all cases, the spiked extracts afforded an initial LLE extract comprised entirely of early eluting material, i.e. components that elute around the 20 minute mark on the HPLC analysis system.
The second LLE extract captured additional quantities of the early eluting components as well as components that eluted up to ∼25 minutes (Fig. 4) . The second extract was also observed to afford minor amounts (< 5% In summary, the first LLE extract is optimized for constituents with log P < 5 but attains this result with a lower yield of desired compounds. The second LLE extract increases yield at the expense of minor amounts of lipophilic material being present.
Fig. 4. Elution profile of: (a) crude extract derived from Botrylloides perspicuum; (b) spiked with brucine (B), eupomatenoid 5 (E5) and eupomatenoid 3 (E3) reference compounds; (c-d) eupomatenoid 3 is retained but a minor amount of eupomatenoid 5 is observed in the second optimized extract.
Before the project moved into full production mode, the number of samples was expanded (198 randomly selected biota) to gauge the protocol's performance against a more diverse set. It was noticed that some crude extracts (typically those derived from marine invertebrates of particular genera) did not fully solubilize in the load solvent resulting in formation of a quantity of precipitate prior to loading on the NVP-DVB sorbent. Applications for HTS and Drug Discovery. The scaled-up optimization protocol employed 300 mg of plant or marine invertebrate, and 400 mg of NVP-DVB copolymer to ultimately yield a set of 70000 natural product LLE extracts from 35000 biota resident in Nature Bank. The subsequent natural product library has since been used in two distinct ways (Fig. 5) .
Fig. 5. Workflow for production of the LLE extracts and subsequent screening.
First, LLE extracts derived from 35000 plant and marine organisms were screened in duplicate to give a campaign of 140000 data points (i.e. 2 × LLE extracts per biota sample = 70000 LLE extracts screened in duplicate) and the ensuing actives analyzed via a process coined 'small scale bioprofiling' [17] . Small scale bioprofiling provided information that could be used to determine if the active compound in an extract was likely to have conventional lead-like properties, to semi-quantify the potency of the bioactive compound and to predict the likely uniqueness of the bioactive component [17] .
For each screening campaign, up to 200 active extracts were processed using a rapid automated C 18 HPLC chromatography protocol. The separated fractions (22 per extract) were then screened and the spectroscopic properties (NMR, MS and nitrogen content) of the active fractions analyzed. Screening of the active fractions allowed the partially purified fraction to be compared with the crude extract.
Screening of LLE extracts in tandem with small scale bioprofiling led to an improvement in the delivery of lead-like compounds with 64% of screens yielding lead-like bioactive compounds [17] .
More recently, a subset of 18453 LLE extracts from the 70: 
Experimental Part
General. Twenty reference compounds within a clog P range between -7.60 and 7.45 were purchased from Sigma-Aldrich (Table 1) . Eupomatenoid 3 and eupomatenoid 5 were isolated in-house and shown to be identical to previously reported material. [23] HPLC grade methanol (MeOH), dichloromethane (DCM) and n-hexane were purchased from Lab-Scan. Dimethyl sulfoxide (DMSO, 99.9%) and trifluoroacetic acid (TFA/H + , 99.5%) were purchased from Fluka and used without further purification.
Water was purified with a Milli-Q system from Millipore. Dried plant and marine invertebrate samples were obtained from Griffith University's Nature Bank (Table 2) Lombardo et al. [12] was used to determine the experimental log P of the 115 natural products.
Reference log P values for drugs and bioactive compounds were obtained from Sangster Research
Laboratories except where stated (Table 1) .
Stock Solutions. The 12 reference compounds used in protocol development were prepared at varying concentrations (mg/ml) in MeOH in an effort to obtain reasonably similar UV peak heights via a diode array detector: brucine (1), capsaicin (1), clotrimazole (5), metaprolol (1), mycophenolic acid (1), rapamycin (1), reserpine (1), paclitaxel (1), theophylline (1), vancomycin (15) , eupomatenoid 3 (1), and eupomatenoid 5 (1). All stock solutions were stored in the dark at 4 o C following preparation. To facilitate fine tuning of the elution conditions through SPE, stock solutions (100 µl) were selected in an ad hoc manner, combined and dried. The resulting mixture was reconstituted with 100 µl DMSO prior to HPLC analyses (vide infra). A stock solution of brucine (0.1 mg/ml), dipyrimadole (0.1 mg/ml) and capsaicin (0.5 mg/ml) was prepared as an internal standard to monitor the production of optimized extracts for HTS.
Crude Extracts. Dried and milled biota samples (300 mg) were placed in an SPE cartridge fitted with a 20 µm frit and a cap applied. Plant biota were extracted at 1 ml/min with n-hexane (7 ml, discarded), followed sequentially by DCM (7 ml) and HPLC MeOH (13 ml). The extracts were collected and dried in the same test tube using a combined Martin Christ Beta-RVC centrifugal evaporator/Alpha 2-4 refrigeration unit. Dried extracts were reconstituted in MeOH (4 ml) and loaded onto a cartridge filled with 900 mg PAG using a Gilson XL4 to remove unwanted polyphenolic compounds [24] . The cartridge was subsequently washed with MeOH (2 × 4 ml) at 5 ml/min and the combined MeOH washes dried under vacuum to afford the crude plant extract. Marine invertebrates were extracted in a similar manner with n-hexane (7 ml, discarded), 80:20 DCM:MeOH (7 ml) and MeOH (13 ml). The vast majority of marine organisms do not contain polyphenolic compounds thereby obviating the need to filter extracts through PAG.
Comparison of Solid-Phase Extraction Sorbents. 120 mg of sorbent (Table 3 ) was pre-weighed into empty SPE cartridges fitted with a 20 µm frit. A second 20 µm frit was placed on top of the sorbent and a cap applied to facilitate automated SPE using the Gilson XL4. The sorbents were conditioned with MeOH and equilibrated with the eluting solvent immediately prior to use. TFA was added to
MeOH:H 2 O mixtures to make a final concentration of 1% during refinement of the eluting solvents.
Each biota specimen was extracted in batches of eight. The resulting dried, crude extracts were reconstituted in MeOH (5 ml) and combined. Eight aliquots (5 ml each) were then removed from the mix to maintain extract uniformity for the comparative study. One fifth (i.e. 1 ml) of each aliquot was tested on each sorbent and the remaining 1/5 retained as an untreated reference. Each batch of biota extracts thus afforded sufficient material to compare eight different eluting conditions on each of the four sorbents.
Sixteen extracts (eight DCM extracts derived from plants and eight DCM:MeOH extracts from marine invertebrates) were initially chosen for this study ( Table 2 ). Eight of the extracts yielded lead-and druglike molecules while the other eight afforded non drug-like, highly lipophilic compounds. A further seven biota (Table 2 ) were selected (one for its high level of lipophilic material; the other six from randomly selected plant and marine organisms) after the comparative SPE investigation had concluded in an effort to fine tune the eluting solvent and also undertake preliminary scale-up testing on a smaller subset. Finally, an additional 198 biota were analyzed to increase biological and chemical diversity, and further refine the eluent conditions for retention of high log P components prior to production of the natural product extract screening library.
HPLC Analysis. All extracts in the screening set were prepared as DMSO solutions to facilitate HTS.
To maintain consistency, all extracts from the comparative SPE sorbent investigation were, likewise, e Used for QC purposes.
f Additional natural products added to the reference set used to develop protocols. b Additional biota extracts (one plant, one animal) containing lipophilic material used as referents for development of protocols to remove high log P components.
___________________________________________________________________________________
c Additional 7 extracts added to set.
d Extracts (6) used for protocol development, spiking experiments and initial scale-up. 
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